Oral corticosteroid therapy and present disease status in myasthenia gravis

Tomihiro Imai, Shigeaki Suzuki, Emiko Tsuda, Yuriko Nagane, Hiroyuki Murai, Masayuki Masuda, Shingo Konno, Yasushi Suzuki, Shunya Nakane, Kazuo Fujihara, Norihiro Suzuki, Kimiaki Utsugisawa

研究成果: Contribution to journalArticle査読

21 被引用数 (Scopus)

抄録

Introduction: The aim of this study was to elucidate the effectiveness of oral prednisolone (PSL) according to dosing regimen in 472 patients with myasthenia gravis (MG). Methods: We compared the clinical characteristics and PSL treatment between 226 patients who achieved minimal manifestations (MM) or better and 246 patients who remained improved (I) or worsened, according to the MG Foundation of America postintervention status. Results: Achievement of MM or better at peak PSL dose (odds ratio 12.25, P<0.0001) and combined use of plasma exchange/plasmapheresis (PE/PP) and/or intravenous immunoglobulin (IVIg) (odds ratio 1.92, P=0.04) were associated positively, and total PSL dose during the past year (odds ratio 0.17, P=0.03) was associated negatively with present MM or better status. Conclusions: Higher PSL dose and longer PSL treatment do not ensure better outcome. In the absence of a good response, the PSL dose should be decreased by combining with modalities such as PE/PP or IVIg.

本文言語英語
ページ(範囲)692-696
ページ数5
ジャーナルMuscle and Nerve
51
5
DOI
出版ステータス出版済み - 5 1 2015

All Science Journal Classification (ASJC) codes

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

フィンガープリント 「Oral corticosteroid therapy and present disease status in myasthenia gravis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル